AR095561A1 - Xantinas sustituidas y su uso en el tratamiento de un trastorno mediado por trpc5 - Google Patents
Xantinas sustituidas y su uso en el tratamiento de un trastorno mediado por trpc5Info
- Publication number
- AR095561A1 AR095561A1 ARP140101183A ARP140101183A AR095561A1 AR 095561 A1 AR095561 A1 AR 095561A1 AR P140101183 A ARP140101183 A AR P140101183A AR P140101183 A ARP140101183 A AR P140101183A AR 095561 A1 AR095561 A1 AR 095561A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroalkyl
- heterocycloalkyl
- dialkylamino
- amido
- Prior art date
Links
- 102000003621 TRPC5 Human genes 0.000 title abstract 3
- 101150042815 TRPC5 gene Proteins 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 5
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 abstract 5
- 125000003368 amide group Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 229940100389 Sulfonylurea Drugs 0.000 abstract 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 3
- 239000004202 carbamide Substances 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000005864 sulfonamidyl group Chemical group 0.000 abstract 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuestos, composiciones y métodos para inhibir el canal iónico TRPC5 y los trastornos relacionados con TRPC5. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde: R¹ es alquilo C₁₋₆, alquenilo C₂₋₆ o alquinilo C₂₋₆, cada uno de los cuales está opcionalmente sustituido con 1 - 4 R³; R² es alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, halo, hidroxilo, alcoxi C₁₋₆, heteroalquilo C₁₋₆, ariloxi C₆₋₁₀, arilalcoxi C₇₋₁₆, amino, alquilamino C₁₋₆, dialquilamino C₂₋₁₂, -C(O)-, -S-, -S-alquilo C₁₋₆, -S(O)-, -S(O)₂-, -O-, heterocicloalquilo, heteroarilo, sulfonamidilo, amido, urea, sulfonilurea, acilo, nitro, ciano, donde cada uno de alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, heteroalquilo C₁₋₆, ariloxi C₆₋₁₀, arilalcoxi C₇₋₁₆, amino, alquilamino C₁₋₆, dialquilamino C₂₋₁₂, -S-, -S-alquilo C₁₋₆, -S(O)-, -S(O)₂-, heterocicloalquilo, heteroarilo, sulfonamidilo, amido, urea, sulfonilurea, acilo, está opcionalmente sustituido con 1 - 3 R³; cada R³ es en forma independiente alquilo C₁₋₆, heteroalquilo C₁₋₆, halo, haloalcoxi C₁₋₆, hidroxilo, alcoxi C₁₋₆, amino, alquilamino C₁₋₆, dialquilamino C₂₋₁₂, ciano, nitro, amido, -S-, -S(O)₂-, -C(O)-, -C(O)O-alquilo C₁₋₆, -C(O)-alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo, fenilo, o naftilo, donde cada uno de alquilo C₁₋₆, heteroalquilo C₁₋₆, haloalcoxi C₁₋₆, alcoxi C₁₋₆, amino, alquilamino C₁₋₆, dialquilamino C₂₋₁₂, amido, -S-, -S(O)₂-, -C(O)-, -C(O)O-alquilo C₁₋₆, -C(O)-alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo, fenilo, o naftilo está opcionalmente sustituido con 1 - 3 R⁴; y cada R⁴ es en forma independiente alquilo C₁₋₆, heteroalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₇, haloalcoxi C₁₋₆, haloalquilo C₁₋₆, heterocicloalquilo, arilo C₆₋₁₀, heteroarilo, cicloalquilalquilo C₄₋₁₀, heterocicloalquilalquilo, arilalquilo C₇₋₁₆, heteroaril-alquilo C₁₋₆, halo, hidroxilo, alcoxi C₁₋₆, hidroxialquilo C₁₋₆, ariloxi C₆₋₁₀, arilalcoxi C₇₋₁₆, alcoxialcoxilo C₂₋₈, amino, alquilamino C₁₋₆, dialquilamino C₂₋₁₂, -S-, -S-alquilo C₁₋₆, -S(O)₂-alquilo C₁₋₆, sulfonamidilo, amido, urea, sulfonilurea, acilo, -C(O)-arilo C₆₋₁₀, -NHC(O)-arilo C₆₋₁₀, -C(O)NH-arilo C₆₋₁₀, -C(O)OH, -C(O)O-alquilo C₁₋₆, -C(O)-alquilo C₁₋₆, acilo, nitro, o ciano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784448P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095561A1 true AR095561A1 (es) | 2015-10-28 |
Family
ID=50819943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101183A AR095561A1 (es) | 2013-03-14 | 2014-03-17 | Xantinas sustituidas y su uso en el tratamiento de un trastorno mediado por trpc5 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140275528A1 (es) |
| EP (1) | EP2970316B1 (es) |
| JP (1) | JP2016513687A (es) |
| AR (1) | AR095561A1 (es) |
| TW (1) | TW201444844A (es) |
| UY (1) | UY35424A (es) |
| WO (1) | WO2014152287A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3180342B1 (en) * | 2014-08-11 | 2019-06-26 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
| WO2016086008A1 (en) * | 2014-11-26 | 2016-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Small molecule aldehyde dehydrogenase inhibitors and methods of use thereof |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| WO2018157800A1 (en) * | 2017-02-28 | 2018-09-07 | National Institute Of Biological Sciences, Beijing | Mlkl inhibitors |
| GB201712110D0 (en) * | 2017-07-27 | 2017-09-13 | Thomas Helledays Stiftelse För Medicinsk Forskning | New compounds and uses |
| AU2018334290A1 (en) | 2017-09-18 | 2020-04-02 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
| CA3093084A1 (en) | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| SG11202109568TA (en) * | 2019-03-20 | 2021-10-28 | Goldfinch Bio Inc | Pyridazinones and methods of use thereof |
| CN113603690B (zh) * | 2021-08-02 | 2022-10-25 | 南开大学 | 一种含黄嘌呤-8-基的(e)-丙烯酸衍生物及其制备方法和应用 |
| CN115636831B (zh) * | 2022-10-27 | 2024-11-08 | 中国药科大学 | 稠合嘧啶二酮类化合物、其用途以及药物组合物 |
| CN116023336A (zh) * | 2022-12-13 | 2023-04-28 | 河北医科大学 | 一种具有Nav1.7钠离子通道靶向抑制作用的化合物及其药物组合物和用途 |
| CN116217575B (zh) * | 2023-01-09 | 2025-01-10 | 广东赛烽医药科技有限公司 | 一种8-溴茶碱的制备方法 |
| KR20250141831A (ko) * | 2023-02-08 | 2025-09-29 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 잔틴계 화합물 및 이의 용도 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1963325A2 (en) * | 2005-12-07 | 2008-09-03 | UCB Pharma, S.A. | Xanthine derivatives, processes for preparing them and their uses |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
-
2014
- 2014-03-13 TW TW103108996A patent/TW201444844A/zh unknown
- 2014-03-13 UY UY0001035424A patent/UY35424A/es not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/027166 patent/WO2014152287A2/en not_active Ceased
- 2014-03-14 JP JP2016502354A patent/JP2016513687A/ja not_active Withdrawn
- 2014-03-14 EP EP14726452.7A patent/EP2970316B1/en not_active Not-in-force
- 2014-03-14 US US14/210,666 patent/US20140275528A1/en not_active Abandoned
- 2014-03-17 AR ARP140101183A patent/AR095561A1/es unknown
-
2016
- 2016-01-30 US US15/011,523 patent/US20160145257A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2970316B1 (en) | 2017-11-08 |
| EP2970316A2 (en) | 2016-01-20 |
| WO2014152287A9 (en) | 2015-04-23 |
| US20140275528A1 (en) | 2014-09-18 |
| US20160145257A1 (en) | 2016-05-26 |
| WO2014152287A2 (en) | 2014-09-25 |
| TW201444844A (zh) | 2014-12-01 |
| WO2014152287A3 (en) | 2014-12-04 |
| WO2014152287A4 (en) | 2015-02-19 |
| JP2016513687A (ja) | 2016-05-16 |
| UY35424A (es) | 2014-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095561A1 (es) | Xantinas sustituidas y su uso en el tratamiento de un trastorno mediado por trpc5 | |
| AR121016A2 (es) | Sales de fenotiazindiaminio y su uso | |
| AR090292A1 (es) | Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| AR117189A1 (es) | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) | |
| AR100244A1 (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| JOP20180009A1 (ar) | مركبات مثبط فيروس hiv | |
| AR106100A1 (es) | Compuestos bicíclicos como inhibidores duales atx / ca | |
| AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
| EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| AR089527A1 (es) | Inhibidores de bromodominios | |
| CO6140024A2 (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer | |
| EA201391395A1 (ru) | Терапевтические соединения | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| ECSP20023795A (es) | Compuesto de pirimidina como inhibidor de las janocinasas | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR097199A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
| EA201790337A1 (ru) | Кристаллические формы ингибиторов глутаминазы | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR093113A1 (es) | Fungicidas sustituidos con tolilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |